What is the recommended IVIG (intravenous immunoglobulin) dose for an adult with common variable immunodeficiency who develops sepsis?

IVIG Dosing for CVID Patients with Sepsis

For adults with common variable immunodeficiency (CVID) who develop sepsis, continue standard CVID replacement therapy at 400-600 mg/kg every 3-4 weeks rather than using high-dose IVIG as adjunctive sepsis treatment, as current evidence does not support IVIG for sepsis management regardless of underlying immunodeficiency status. 1, 2

Standard CVID Replacement Therapy

Maintain baseline immunoglobulin replacement during sepsis treatment:

• Dose: 300-600 mg/kg (typically 400 mg/kg) administered intravenously every 3-4 weeks 3
• This represents continuation of standard CVID management, not adjunctive sepsis therapy 4, 3
• Target trough IgG levels of 5-7 g/L to prevent infections 5

The FDA-approved dosing for CVID specifically states 300-600 mg/kg every 3-4 weeks for primary humoral immunodeficiency diseases including CVID 3. Studies demonstrate that the standard 400 mg/kg dose significantly reduces lower respiratory tract and severe infections compared to lower doses 5.

Why NOT High-Dose IVIG for Sepsis

Current guidelines explicitly recommend against IVIG as adjunctive sepsis therapy:

• The 2016 Surviving Sepsis Campaign guidelines state: "We suggest against the use of IV immunoglobulins in patients with sepsis or septic shock" (weak recommendation, low quality evidence) 1, 2
• This recommendation applies to all sepsis patients, including those with immunodeficiency 1
• The IDSA guidelines for MRSA infections note that IVIG is "not routinely recommended as adjunctive therapy for the management of invasive MRSA disease," though some experts may consider it in severe sepsis scenarios (C-III evidence) 6, 7

Recent expert consensus on sepsis-induced immunosuppression specifically recommends against immunoglobulin for immunomodulatory therapy in septic patients 8.

Evidence Against High-Dose IVIG in Sepsis

The evidence base reveals significant limitations:

• Meta-analyses showing mortality benefit had "moderate-to-high risk of bias" 8
• When high-quality studies were analyzed separately, IVIG showed no mortality benefit (OR = 0.96; 95% CI 0.71-1.3) 8
• The INSTINCT study found that IVIG (25 g/day for 3 days) did not reduce 180-day mortality 8
• Low-dose IVIG (0.3 g/kg total) showed no difference in outcomes between patients with and without hypogammaglobulinemia 9

While one network meta-analysis suggested optimal dosing at 1.5-2 g/kg total 10, this conflicts with guideline recommendations and more rigorous systematic reviews 1, 8.

Clinical Management Algorithm

For CVID patients developing sepsis:

1. Continue standard CVID replacement: 400-600 mg/kg IV every 3-4 weeks 3
2. Aggressive antimicrobial therapy: Prolonged courses should be considered for immunocompromised hosts 4
3. Standard sepsis management: Follow Surviving Sepsis Campaign guidelines for fluid resuscitation, vasopressors, and source control 1
4. Monitor trough IgG levels: Ensure adequate replacement therapy (target 5-7 g/L) 5

Important Caveats

IgA deficiency considerations:

• Check serum IgA levels before IVIG administration 11
• IgA deficiency with anti-IgA antibodies can cause severe anaphylaxis 4, 3
• Use IgA-depleted preparations if IgA deficiency is detected 11

Renal function monitoring:

• Ensure patients are not volume depleted before IVIG infusion 3
• Monitor renal function (BUN/creatinine) before and during therapy 3
• Consider slower infusion rates in patients at risk for renal dysfunction 3

Glucose monitoring:

• IVIG containing maltose can cause falsely elevated glucose readings with certain testing systems 3
• Use glucose-specific testing methods (not GDH-PQQ based) 3